antitrust
Interview: Will patent filers have to change practices after European Commission’s €462.6 million fine against big pharma’s Teva?
By AWA | Posted on November 26, 2024
The European Commission recently fined pharmaceutical giant Teva €462.6 million for artificially extending patent protection by pursuing divisionals and spreading misleading information about a competing product to hinder its market entry and uptake. Margrethe Vestager, the Commission’s Executive Vice-President in charge of competition policy, commented that the decision “reaffirms the Commission’s commitment to competition enforcement...
Filed under: Insights, Interviews
Tags: antitrust, competition, divisionals, EU, patents, Teva
Recent contributors
Senior Associate, Attorney at Law
Partner, Attorney at Law, Group Vice President
Partner, Attorney at Law, Business Area Manager
Senior Counsel, European Patent Attorney
Partner, European Patent Attorney, UPC Representative, Business Area Manager